MGF (Mechano Growth Factor)
Mechano Growth Factor · IGF-1 Splice Variant
Overview
Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.
Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair. The E-peptide domain exhibits distinct activity from mature IGF-1.
Primary mechanism activating dormant muscle satellite cells which fuse to damaged fibers.
Short half-life means effects are concentrated at injection site.
Naturally upregulated after mechanical stress; supplementation enhances repair processes.
Animal studies suggest improved tendon injury outcomes when applied locally.
Mechanism
Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.
Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair. The E-peptide domain exhibits distinct activity from mature IGF-1.
Primary mechanism activating dormant muscle satellite cells which fuse to damaged fibers.
Research areas
- Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.
- Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair. The E-peptide domain exhibits distinct activity from mature IGF-1.
- Primary mechanism activating dormant muscle satellite cells which fuse to damaged fibers.
- Short half-life means effects are concentrated at injection site.
- Naturally upregulated after mechanical stress; supplementation enhances repair processes.
- Animal studies suggest improved tendon injury outcomes when applied locally.
- Research indicates potential for bone healing via osteoblast regulation.
Research notes
- Injection site soreness
- Mild fatigue
- Any unusual growths, lumps, or rapid tissue changes
- Severe injection site reactions
- Persistent headaches or vision changes
- Signs of hypoglycemia
- Any history of cancer or neoplastic disease
- Pregnancy or breastfeeding
- Uncontrolled diabetes
Pharmacokinetics
- Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.
- Short half-life means effects are concentrated at injection site.
FAQs
Why is MGF injected directly into muscles post-workout?
MGF has a 5-7 minute half-life and activates satellite stem cells locally at the injection site. Post-workout timing is critical because muscles are primed for growth and recovery. Direct intramuscular injection confines effects to the trained muscle group you want to develop.
How is MGF different from PEG-MGF?
Standard MGF has a 5-7 minute half-life requiring daily injections. PEG-MGF (pegylated) lasts much longer (hours). Choose based on protocol preference: frequent localized doses (MGF) or fewer higher-dose injections (PEG-MGF). Effects are similar; administration differs.
Can MGF cause hypoglycemia?
Possibly, though less likely than IGF-1 LR3 due to MGF's very short half-life and localized action. However, the post-workout window and direct muscle injection make hypoglycemia unlikely. Still monitor early use and consume carbs post-injection as a precaution.
How long do I need to use MGF to see muscle growth?
Week 1-2 shows reduced soreness in targeted muscles. Week 4-8 shows noticeable improvements in trained muscle size and recovery capacity. Most users run 8-12 week cycles with equal off-time. Structural gains from satellite cell activation may persist after discontinuation.